|
Market Closed -
Nasdaq
16:30:00 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 0.4936 USD | -8.22% |
|
-8.86% | -42.13% |
| 10-14 | Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target | MT |
| 08-28 | Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | CI |
| Market Cap | 6.21M 5.57M 5.14M 4.65M 8.69M 592M 8.83M 61.27M 24.44M 310M 23.32M 22.83M 981M | P/E 2026 * |
-1.47x | P/E 2027 * | -1.36x |
|---|---|---|---|---|---|
| Enterprise Value | 6.21M 5.57M 5.14M 4.65M 8.69M 592M 8.83M 61.27M 24.44M 310M 23.32M 22.83M 981M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
83.56% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| APRE | Delayed | |
CBOE
| APRE | Real-time |
| 1 day | -8.22% | ||
| 1 week | -8.86% | ||
| Current month | -34.19% | ||
| 1 month | -35.86% | ||
| 3 months | -20.52% | ||
| 6 months | -39.73% | ||
| Current year | -42.13% |
| 1 week | 0.41 |  | 0.54 |
| 1 month | 0.41 | | 0.78 |
| Current year | 0.41 | | 1.49 |
| 1 year | 0.41 | | 1.49 |
| 3 years | 0.41 | | 8.85 |
| 5 years | 0.41 | | 25.8 |
| 10 years | 0.41 | | 25.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 57 | 2022-06-28 |
John Hamill
DFI | Director of Finance/CFO | 62 | 2023-01-29 |
Brian Wiley
PRN | Corporate Officer/Principal | 58 | 2023-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 69 | 2014-12-31 |
John Henneman
BRD | Director/Board Member | 65 | 2019-07-31 |
Richard Peters
CHM | Chairman | 63 | 2023-08-22 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/16/26 | Free | Director | 15,690 | 0.1267% | ||
| 3/31/26 | Buy | Chairman | 247,830 | 2.1642% | ||
| 3/31/26 | Buy | Chief Financial Officer | 61,956 | 0.5410% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.22% | -8.86% | -65.96% | -86.05% | 6.77M | |
| +0.34% | +1.12% | +34.75% | +61.06% | 64.14B | |
| +0.98% | +2.68% | +12.25% | +82.98% | 55.53B | |
| +1.75% | +2.01% | +13.30% | +103.69% | 53.03B | |
| -1.43% | -1.17% | +26.27% | +52.86% | 45.99B | |
| -0.48% | -2.80% | +18.01% | +117.99% | 42.45B | |
| +0.82% | +1.37% | +227.94% | +922.41% | 40.45B | |
| -0.26% | -2.57% | +12.55% | +45.18% | 32.25B | |
| -2.07% | +44.58% | +102.84% | +88.74% | 34.47B | |
| -2.72% | -0.44% | +22.58% | -5.63% | 24.23B | |
| Average | -1.13% | +3.04% | +40.45% | +138.32% | 39.25B | |
| Weighted average by Cap. | -0.08% | +3.13% | +49.18% | +160.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -16.07M -14.39M -13.28M -12.01M -22.47M -1.53B -22.83M -158M -63.19M -801M -60.3M -59.02M -2.54B | -22.52M -20.17M -18.61M -16.84M -31.49M -2.14B -31.99M -222M -88.56M -1.12B -84.5M -82.7M -3.55B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-29 | US$0.4936 | -8.22% | 171,057 |
| 26-10-28 | US$0.5378 | +4.83% | 147,500 |
| 26-10-27 | US$0.5130 | +14.25% | 187,912 |
| 26-10-26 | US$0.4490 | -13.27% | 568,671 |
| 26-10-23 | US$0.5177 | -4.41% | 89,183 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- APRE Stock
Select your edition
All financial news and data tailored to specific country editions
